Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    astellas | peanut
Previous Study | Return to List | Next Study

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03755713
Recruitment Status : Recruiting
First Posted : November 28, 2018
Last Update Posted : July 18, 2019
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.

Condition or disease Intervention/treatment Phase
Peanut Allergy Drug: ASP0892 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
Actual Study Start Date : February 21, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: ASP0892 Low Dose (Cohort A)
Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
Drug: ASP0892
Intradermal

Experimental: ASP0892 High Dose (Cohort B)
After all participants in cohort A complete study procedures, the DMC will review the safety and tolerability data and provide recommendations depending on the nature, frequency and severity of the safety profile reviewed. Recommendations will be to proceed with escalation to the next higher dose or stop dose escalation (i.e., no further dosing with study drug).
Drug: ASP0892
Intradermal

Placebo Comparator: Placebo
Each cohort will consist of 10 participants (ASP0892 n = 8 and placebo n = 2). The data will be assessed by the Data Monitoring Committee (DMC) after all enrolled cohort A participants complete visits through day 43. Assessments for safety, tolerability, and dose escalation will occur prior to beginning cohort B.
Drug: Placebo
Intradermal; normal saline solution




Primary Outcome Measures :
  1. Safety as assessed by Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to Day 576 ]
    Adverse Events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). AEs starting or worsening after the first dose of study drug up through study completion will be considered treatment-emergent.

  2. Safety as assessed by local reactogenicity reactions [ Time Frame: Up to Day 50 ]
    Participants will be asked to record local reactogenicity (pain, tenderness; erythema/redness, Induration/Swelling) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (Potentially Life Threatening).

  3. Safety as assessed by systemic reactogenicity reactions [ Time Frame: Up to Day 50 ]
    Participants will be asked to record systemic reactogenicity (nausea/vomiting, diarrhea, headache, fatigue, myalgia) on a daily basis for 7 consecutive days after the injection, each treatment will be summarized. Grades range from 1 (mild) to 4 (Potentially Life Threatening).

  4. Number of participants with vital signs abnormalities and/or adverse events [ Time Frame: Up to Day 576 ]
    Number of participants with potentially clinically significant vital sign values.

  5. Number of participants with laboratory value abnormalities and/or adverse events [ Time Frame: Up to Day 576 ]
    Number of participants with potentially clinically significant laboratory values.

  6. Safety assessed by Anti-LAMP-1 antibody [ Time Frame: Up to Day 576 ]
    Anti-LAMP-1 antibody formation for all participants will be summarized for each treatment by visit using descriptive statistics.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a body mass index (BMI) ≥ 3rd percentile and ≤ 97th percentile.
  • Subject has a physician-diagnosed peanut allergy or history of peanut allergy. Subjects with history of nonsevere anaphylaxis (Grade ≤ 3) to peanuts (including mild wheezing or dyspnea without hypoxia) will be enrolled.
  • Subject has an anti-Ara h2 Immunoglobulin E (IgE) measured by ImmunoCAP > 0.35 kU/L.
  • Subject has a positive Skin prick test (SPT) to peanut with a change in wheal diameter ≥ 3 mm as compared to a negative control.
  • Subject has a positive peanut Double-blinded placebo-controlled food challenge (DBPCFC) at Screen 2 visit with an eliciting dose ≤ 300 mg peanut protein (≤ 444 mg cumulative reactive dose [CRD]).
  • Female subject must either:

    • Be of non-childbearing potential, clearly premenarchal; documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
    • Or, if of childbearing potential, agrees not to try to become pregnant during the study; and have a negative urine pregnancy test at screening and at day 1 (predose); and if heterosexually active, agrees to consistently use 1 form of highly effective birth control starting at screening and throughout the study period.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 28 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 28 days after the final study drug administration.
  • A heterosexually active male subject with female partner(s) who are of childbearing potential is eligible if:

    • Agrees to use a male condom starting at screening and continue throughout study treatment and for 28 days after the final study drug administration. If the male subject has not had a vasectomy or is not sterile, the subjects female partner(s) is utilizing 1 form of highly effective birth control starting at screening and continue throughout study treatment and for 90 days after the male subject receives his final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period, and for 90 days after the final drug administration.
  • Subject and subject's parent(s) or legal guardian agree that the subject will not participate in another interventional study while participating in the present study.

Exclusion Criteria:

  • Subject has severe anaphylaxis to peanuts (Grades 4 or 5 including dyspnea associated with hypoxia, cyanosis, hypotension or neurological compromise) per the Grading of Food-Induced Anaphylaxis According to Severity of Clinical Symptoms based on historical clinical symptoms.
  • Subject develops a Grade 4 or 5 reaction during the DBPCFC, per the Grading of Food- Induced Anaphylaxis According to Severity of Clinical Symptoms based on historical clinical symptoms.
  • Subject has received or is planning to receive administration of any vaccine (other than injectable Influenza vaccine) from 28 days prior to the first dose through 2 weeks after the last dose of the study vaccine.
  • Subject received any specific immunotherapy for allergy (e.g., epicutaneous immunotherapy [EPIT], sublingual immunotherapy [SLIT], Subcutaneous immunotherapy [SCIT] and oral immunotherapy [OIT]) during the past 12 months, currently or plans to receive during the course of the study.
  • Subject has used the following drug(s) prior to the dosing of the study vaccine:

    • Within 2 months prior to study vaccine administration: Systemic (or inhaled) steroid, chemical mediator-isolation inhibitor, T helper cell type 2 (Th2) cytokine inhibitor, thromboxane A2 synthesis inhibitor, thromboxane A2 receptor antagonist, β-blocker, angiotensin-converting enzyme inhibitors and/or angiotensin-receptor blockers
    • Within 3 months prior to study vaccine administration: Biologics and/or immune modulators (including anti-TNFα antibody and anti-IgE monoclonal antibody)
  • Subject has history of allergic reactions such as anaphylactic shock, angioedema with airway constriction or hypotension caused by food other than peanut and/or medical products (including vaccine) in the past.
  • Subject's laboratory test results at screening or prior to study drug dosing on day 1 are outside the normal limits and are considered clinically significant.
  • Subjects with anti-Lysosomal associated membrane protein (LAMP)-1 antibodies above the cut-point for the Tier 1 assay and who are confirmed positive in the Tier 2 assay at Screen 1 visit (baseline).
  • Subject had a positive test result for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) antigen/antibody.
  • Subject had a positive urine drug screen result.
  • Subject has immune disorders (including autoimmune disease) and/or diseases requiring immunosuppressive drugs.
  • Subject was diagnosed with immunodeficiency in the past.
  • Subject has uncontrolled hypertension.
  • Subject has a history of cardiovascular disease, arrhythmias, chronic lung disease, active eosinophilic gastrointestinal disease or any other medical or surgical conditions, which, places the subject at increased risk for participation in the study.
  • Subject has a complication or medical history of respiratory disease, which requires medical treatment.
  • Subject has a complication or medical history of malignant tumor.
  • Subject has mental conditions such as schizophrenia, bipolar disorder, dementia or major depressive disorder.
  • Subject has severe or poorly controlled atopic dermatitis or generalized eczema.
  • Subject is unable to discontinue antihistamines within 7 days or 5 half-lives (whichever duration is longer) prior to SPT and oral food challenge procedures.
  • Subject has asthma other than mild intermittent asthma (National Heart, Lung and Blood Institute [NHLBI] Guidelines, July 2007) and has a forced expiratory volume in 1 second value < 80% and/or requiring chronic maintenance treatment (i.e., inhaled corticosteroids).
  • Subject has already received injection of Lysosomal associated membrane protein (LAMP)-vax such as ASP0892.
  • Subject has received investigational therapy within 35 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject's parent(s) or legal guardian is an employee of the Astellas Group or vendors involved in the study.
  • Subject has any condition, which, makes the subject unsuitable for study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03755713


Contacts
Layout table for location contacts
Contact: Astellas Pharma Global Development, Inc. 800-888-7704 astellas.registration@astellas.com

Locations
Layout table for location information
United States, Arkansas
Arkansas Children's Hospital Research Institute Recruiting
Little Rock, Arkansas, United States, 72205
United States, California
Sean N Parker Center for Allergy & Asthma Research, LPCH El Camino Hospital Recruiting
Mountain View, California, United States, 94090
United States, Illinois
The University of Chicago Medicine Recruiting
Chicago, Illinois, United States, 60637
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, New York
Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45241
United States, Washington
Asthma, Inc. Recruiting
Seattle, Washington, United States, 98115
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Monitor, Senior Medical Director Astellas Pharma Global Development, Inc.

Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT03755713     History of Changes
Other Study ID Numbers: 0892-CL-1002
First Posted: November 28, 2018    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
ASP0892
Peanut Allergy

Additional relevant MeSH terms:
Layout table for MeSH terms
Peanut Hypersensitivity
Nut and Peanut Hypersensitivity
Food Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases